C.R. Bard, Inc. (NYSE:BCR) VP Frank Lupisella, Jr. sold 9,173 shares of the firm’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $325.00, for a total transaction of $2,981,225.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

C.R. Bard, Inc. (NYSE BCR) traded up 0.53% during trading on Friday, hitting $329.05. 135,155 shares of the stock traded hands. The firm has a market cap of $23.91 billion, a PE ratio of 43.20 and a beta of 0.58. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $329.09. The firm has a 50-day moving average price of $321.11 and a 200 day moving average price of $309.80.

C.R. Bard (NYSE:BCR) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the Zacks’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same quarter in the prior year, the company posted $2.54 earnings per share. C.R. Bard’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities analysts forecast that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.32%. C.R. Bard’s payout ratio is 13.67%.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/20/frank-lupisella-jr-sells-9173-shares-of-c-r-bard-inc-bcr-stock.html.

A number of large investors have recently bought and sold shares of the stock. Curbstone Financial Management Corp lifted its position in C.R. Bard by 28.8% during the third quarter. Curbstone Financial Management Corp now owns 2,750 shares of the medical instruments supplier’s stock valued at $881,000 after acquiring an additional 615 shares during the last quarter. Yorkville Capital Management LLC purchased a new stake in C.R. Bard during the second quarter valued at approximately $1,043,000. Paulson & CO. Inc. purchased a new stake in C.R. Bard during the second quarter valued at approximately $13,315,000. Toronto Dominion Bank lifted its position in C.R. Bard by 26.1% during the second quarter. Toronto Dominion Bank now owns 24,528 shares of the medical instruments supplier’s stock valued at $7,752,000 after acquiring an additional 5,077 shares during the last quarter. Finally, Banco BTG Pactual S.A. purchased a new stake in C.R. Bard during the second quarter valued at approximately $7,271,000. 79.22% of the stock is owned by institutional investors.

Several analysts have commented on BCR shares. BidaskClub lowered shares of C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Jefferies Group LLC restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Thursday, September 14th. BMO Capital Markets reiterated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a report on Tuesday, July 11th. Finally, Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $292.00.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.